Medication info
Memantine Tablets (Memantine Hydrochloride)

Memantine Tablets (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›10mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
For domestic use: 30 tablets/bottle, 100 tablets/bottle; for export: 30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 200612313 · Notified 2006.12.12 · Insurance code 649805440

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver can periodically confirm that the patient is taking the medicine. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed periodically. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. First week (days 1-7): Administer 5mg once daily for 7 days. Second week (days 8-14): Administer 10mg daily (5mg twice daily) for 7 days. Third week (days 15-21): Administer 15mg daily (10mg in the morning and 5mg in the evening) for 7 days. From the fourth week onward: Administer 20mg daily (10mg twice daily). Maintenance dose: The recommended maintenance dose is 20mg daily (10mg twice daily). 2. Elderly patients: Based on clinical data, the recommended dose for elderly patients aged 65 years and older is 20mg daily (10mg twice daily). 3. Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation method. In patients with severe renal impairment (creatinine clearance 5-30 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer’s disease
View approved original text

This medication is used for the treatment of moderate to severe Alzheimer’s disease. It helps improve memory decline and cognitive dysfunction, contributing to enhancing the patient's ability to perform daily activities. It slows the progression of symptoms and helps patients maintain a more stable condition. Expected effects can be achieved with regular use under a physician's prescription. Such treatment positively impacts the quality of life for both the patient and the caregiver.

How to take

Adult dose

Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver can periodically confirm that the patient is taking the medicine. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed periodically. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. First week (days 1-7): Administer 5mg once daily for 7 days. Second week (days 8-14): Administer 10mg daily (5mg twice daily) for 7 days. Third week (days 15-21): Administer 15mg daily (10mg in the morning and 5mg in the evening) for 7 days. From the fourth week onward: Administer 20mg daily (10mg twice daily). Maintenance dose: The recommended maintenance dose is 20mg daily (10mg twice daily). 2. Elderly patients: Based on clinical data, the recommended dose for elderly patients aged 65 years and older is 20mg daily (10mg twice daily). 3. Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation method. In patients with severe renal impairment (creatinine clearance 5-30 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Precautions

This medication should not be used in patients with known allergies to its components. It should not be administered to patients with severely impaired liver function or very poor kidney function. Since it contains lactose, individuals with certain genetic lactose-related disorders should not take it. Patients with epilepsy or a history of seizures should use this drug with caution. Additionally, it is advisable not to take this medication with other drugs that have similar effects, as it may increase side effects. Patients with altered urine acidity or heart disease should also exercise caution. While taking this medication, side effects such as dizziness, headache, constipation, drowsiness, and high blood pressure may occur, and if symptoms are severe, medical consultation is advised. This medication can interact with other drugs, so it is crucial to inform your doctor of any other medications being taken, especially when used with specific psychiatric medications or antihypertensives. Women who are pregnant or may become pregnant should only use this medication if necessary, as it may affect the fetus. Nursing mothers are advised to discontinue breastfeeding while using this medication. Safety in pediatric or adolescent patients under 18 years of age has not been established. In case of overdose, central nervous system symptoms or gastrointestinal symptoms may appear, so it is important to avoid exceeding the recommended dosage and to visit a medical facility immediately if overdose occurs. This medication can affect the patient’s reaction speed, so caution is needed when driving or operating machinery. Finally, this medication should be stored out of reach of children and in its original packaging to maintain quality.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • drowsiness
  • confusion
  • hallucination
Show 31 more
  • psychiatric reaction
  • dizziness
  • balance disorder
  • gait abnormalities
  • seizures
  • heart failure
  • hypertension
  • venous thrombosis/thromboembolism
  • dyspnea
  • constipation
  • vomiting
  • pancreatitis
  • elevated liver function test values
  • hepatitis
  • headache
  • fatigue
  • lassitude
  • weakness
  • diarrhea
  • confusion
  • drowsiness
  • anxiety
  • aggression
  • hallucination
  • gait disorder
  • restlessness
  • psychosis
  • visual hallucination
  • convulsion
  • stupor
  • unconsciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and humidity. It is recommended to maintain storage temperatures between 1 and 30 degrees Celsius. This will help preserve the efficacy and safety of the drug for a long time.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

For domestic use: 30 tablets/bottle, 100 tablets/bottle; for export: 30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.